Good MorningEquity markets continue to tread water beneath significant resistance points as investors weigh the onslaught of earnings reports. While most reports are better than expected, the news is often mixed regarding analysts' expectations, and guidance is more in line with the consensus than not. In the eyes of a market that needs improvements, the news is ok but not enough to spur a sustainable rally.
Next week will be a challenge for the market. Not only does the Q1 reporting season kick into high gear, but the PCE Price Index is due out on Friday. Given the state of inflation and interest rates, this reading may be more important than ever. A hot report, or even one that is only slightly cooler than before, may not be enough to excite investors. With high inflation, the market needs to expect interest rates to remain high and that general demand will continue to decline. Featured: The Robotics Revolution has arrived (Ad) 
|
Markets | | Rail unions want railroads to take some of the billions they’re using every year to buy back their stock and use it to improve safety in the wake of several high-profile derailments and hire more workers Read the Full Story |
|
From Our PartnersJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%...
Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry." | | Click here to watch the demo… |
|
Tech | | Stocks capped a listless day of trading Friday with slight gains for the major stock indexes, closing out a quiet week on Wall Street highlighted by a batch of mostly mixed corporate earnings reports.The S&P 500, Dow Jones Industrial Average and Nasdaq composite all gained 0.1% after drifting be... Read the Full Story |
|
Markets | |
IBM’s (NYSE: IBM) share price is struggling to hold gains inspired by the Q1 earnings report, and they may move lower but don’t take this as a signal to sell. The results failed to sustain a rally, but they aren’t bad. The results are mixed; IBM isn’t growing fast, but who ... Read the Full Story |
|
|
Markets | |
Shares of Philip Morris International, Inc. (NYSE: PM) are trying to stage a recovery after falling 5% in pre-market trading on April 20. This came after the company reported mixed results in its first quarter earnings. However, prior to the sell-off, PM stock was beating the S&P 500 index ove... Read the Full Story |
|
Markets | |
Genuine Parts Company (NYSE: GPC) has had its share of ups and downs, but along the way, it has proven the value of Dividend Kings. Dividend Kings and their 50+ year history of distribution increases have proved an ability to operate in all markets, a willingness to change with the times, and the ... Read the Full Story |
|
|
Markets | | CSX hauled in 15% more profit in the first quarter as the railroad's higher rates and fuel surcharges offset its higher costs.The Jacksonville, Florida-based railroad said Thursday that it earned $987 million, or 48 cents per share. That's up from $859 million, or 39 cents per share, a year ago.That... Read the Full Story |
|
Tech | | Pulitzer Prize winning digital media outlet BuzzFeed News is being shut down as part of a cost-cutting drive by its corporate parent that’s shedding about 15% of its entire staff, adding to layoffs made earlier this year. In a memo sent to staff, Buzzfeed Inc. co-founder and CEO Jonah Peretti said T... Read the Full Story |
|
Markets | | Netflix began the year with another burst in subscriber growth that eclipsed analysts’ projections for the third consecutive quarter, providing further evidence the video streaming service has regained its momentum after a jarring downturn in customers prompted a shake up.The 1.75 million gain in Ne... Read the Full Story |
|
Markets | |
As good as D.R. Horton’s (NYSE: DHI) Q2 results and outlook are, the home building industry is rushing toward a cliff that points to slowing sales over the long term. Supply/demand imbalances aside, the rise of inflation and interest rates is hurting the market; the quarterly strength is due... Read the Full Story |
|
Markets | |
Consumer spending usually follows close behind when the economic cycle swings from expansion to contraction. As discretionary and corporate spending increases, American Express (NYSE: AXP) is able to report a total 16% network growth rate annually in its first quarter earnings resul... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California. | View Today's Stock Pick |
|